Sotyktu: which tox species, and why?

“Deucravacitinib was evaluated in two pivotal repeat-dose general toxicity studies, one in rats and the other in monkeys.”

“All metabolites present in humans were present in at least 1 of the nonclinical safety species, with every human metabolite being detected in rats, and there were no unique human metabolites.”

“In the 6-month rat toxicity study, deucravacitinib was orally administered at the doses of 0, 5, 15, and 50 mg/kg, once daily.”